Results 21 to 30 of about 15,511 (169)

DR(E)SS AO ABACAVIR CONFIRMADO POR TESTES EPICUTÂNEOS [PDF]

Revista da Sociedade Portuguesa de Dermatologia e Venereologia, 2014
A reacção de hipersensibilidade (HS) ao abacavir é uma doença sistémica, potencialmente fatal, que ocorre em 2-9% dos doentes expostos. Inicia-se nas primeiras 6 semanas de tratamento e assemelha-se clinicamente ao DRESS, no entanto, sem eosinofilia.
Leonor Ramos, M. M. Brites, J. Oliveira, Margarida Gonçalo   +3 more
doaj   +2 more sources

Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide Repertoire

Frontiers in Immunology, 2021
Abacavir hypersensitivity syndrome can occur in individuals expressing the HLA-B*57:01 major histocompatibility complex class I allotype when utilising the drug abacavir as a part of their anti-retroviral regimen. The drug is known to bind within the HLA-
Patricia T. Illing, Andy van Hateren, Rachel Darley, Nathan P. Croft, Nicole A. Mifsud, Samuel King, Lyudmila Kostenko, Mandvi Bharadwaj, James McCluskey, Tim Elliott, Tim Elliott, Anthony W. Purcell   +11 more
doaj   +1 more source

Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity. [PDF]

PLoS ONE, 2015
Immune mediated adverse drug reactions (IM-ADRs) remain a significant source of patient morbidity that have more recently been shown to be associated with specific class I and/or II human leukocyte antigen (HLA) alleles. Abacavir-induced hypersensitivity
Imir G Metushi, Amanda Wriston, Priyanka Banerjee, Bjoern Oliver Gohlke, A Michelle English, Andrew Lucas, Carrie Moore, John Sidney, Soren Buus, David A Ostrov, Simon Mallal, Elizabeth Phillips, Jeffrey Shabanowitz, Donald F Hunt, Robert Preissner, Bjoern Peters   +15 more
doaj   +1 more source

Comparison of pharmacogenomic guidance in Australian prescribing resources and international pharmacogenomic guidelines. [PDF]

Intern Med J
Abstract Background Pharmacogenomic‐guided medication management optimises drug therapy to enhance patient outcomes. Despite clinical utility, implementation in Australia remains limited, partly due to the lack of clear and consistent guidance. Aim This study evaluated the presence and consistency of pharmacogenomic testing indication categories and ...
Soueid R, Thomas JLA, Hesson LB, Hughes S, Stocker SL.   +4 more
europepmc   +2 more sources

Comparison of Chemical and Electrochemical Approaches to Abacavir Oxidative Stability Testing

Sensors, 2023
A novel electrochemical approach using two different electrode materials, platinum and boron-doped diamond (BDD), was employed to study the oxidative stability of the drug abacavir.
Lucie Pražáková, Jan Fischer, Andrew Taylor, Anna Kubíčková   +3 more
doaj   +1 more source

Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptors

Communications Biology, 2022
HLA-B*57:01 restricted EBV-specific T-cell receptor specificity is altered by abacavir, suggesting a potentially inhibitory effect of abacavir on HLA-B*57:01 restricted TCR recognition.
Anuradha Sooda, Francois Rwandamuriye, Celestine N. Wanjalla, Lichen Jing, David M. Koelle, Bjoern Peters, Shay Leary, Abha Chopra, Michael A. Calderwood, Simon A. Mallal, Rebecca Pavlos, Mark Watson, Elizabeth J. Phillips, Alec J. Redwood   +13 more
doaj   +1 more source

Prospective genetic screening decreases the incidence of Abacavir hypersensitivity reactions in the Western Australian HIV cohort study [PDF]

, 2005
Abacavir therapy is associated with significant drug hypersensitivity in ∼8% of recipients, with retrospective studies indicating a strong genetic association with the HLA-B*5701 allelle.
McKinnon, E., Martin, A., Nolan, D., Rauch, A, Almeida, C., McKinnon, E, Rauch, A., Martin, A, Almeida, C, Nolan, D, Mallal, Simon, Mallal, S.   +11 more
core   +2 more sources

Repositioning of Etravirine as a Potential CK1ε Inhibitor by Virtual Screening

Pharmaceuticals, 2021
CK1ε is a key regulator of WNT/β-catenin and other pathways that are linked to tumor progression; thus, CK1ε is considered a target for the development of antineoplastic therapies.
Luis Córdova-Bahena, Axel A. Sánchez-Álvarez, Angel J. Ruiz-Moreno, Marco A. Velasco-Velázquez   +3 more
doaj   +1 more source

Comparison of the Effects of Three Dual-Nucleos(t)ide Reverse Transcriptase Inhibitor Backbones on Placenta Mitochondria Toxicity and Oxidative Stress Using a Mouse Pregnancy Model

Pharmaceutics, 2022
Nucleos(t)ide reverse transcriptase inhibitors (NRTIs) are the backbone of HIV antiretroviral therapy (ART). ART use in pregnancy has been associated with adverse birth outcomes, in part due to NRTI-induced mitochondrial toxicity.
Kayode Balogun, Lena Serghides
doaj   +1 more source

Low frequency of hypersensitivity reactions to abacavir in HIV infected patients in a referral center in Bahia, Brazil

Brazilian Journal of Infectious Diseases, 2019
Abacavir can cause a multi-systemic hypersensitivity reaction (HSR) in 5–8% of the patients, which is related to HLA-B*57-01 allele. In Brazil, the HLA-B*57-01 screening test became available only in March 2018, several years after abacavir was in use ...
Raphael Gusmão Barreto, Carlos Brites
doaj   +1 more source